BioSpace News Archive

Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the successful completion of the safety phase and the enrollment of new patients into the expansion of the Phase 2 Clinical Trial Combining Precision Biologics NEO-201 monoclonal antibody with Pembrolizumab (Keytruda).

NewStem joins MSK Innovation Hub in collaboration to advance stem cell-based diagnostics that will increase cancer treatment efficacy

Valencia Technologies Corporation announced today that the Centers for Medicare & Medicaid Services (CMS), Division of Outpatient Care issued a letter in response to Valencia Technologies’ New Technology APC application stating the eCoin technology did not qualify for a New Technology APC assignment because it is already described by existing CPT® code 64590.

Solve Therapeutics, Inc. (SolveTx), an oncology-focused biopharmaceutical company, announced today its mission to develop novel antibody-based therapies targeting tumor-specific antigens.

BioSyent Inc. is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive Distribution Agreement with a European partner for a product that is used in oncology supportive care.

Miromatrix Medical Inc. (NASDAQ: MIRO) today announced that it was informed via e-mail from the U.S. Food and Drug Administration (FDA) that the miroliverELAPtm Investigational New Drug (IND) application for the treatment of acute liver failure has been placed on clinical hold.

Axcella Therapeutics, a biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announces a repositioning of its strategy to focus on Long COVID and realize value from its platform and current programs.

Immix Biopharma, Inc. announced that it has in-licensed BCMA-targeted next-generation CAR-T therapy NXC-201 with 85% overall response rate and 71% complete response/stringent complete response at the therapeutic dose from the first 20 patients in an ongoing phase 1b relapsed/refractory multiple myeloma ongoing clinical trial as of June 27, 2022 data cutoff with a median of 6 prior lines of therapy.

Discovery Life Sciences™ announced the launch of its new Proteomic Services Division and is now accepting samples from pharmaceutical and biotech companies, government, and non-profit and academic research centers.

Menarini Silicon Biosystems, a pioneer of liquid biopsy and single cell technologies, announced today the results of a study in which enumeration and genomic characterization of CTCs at varying stages of MM represents an invaluable tool to predict disease aggressiveness and pathology.